
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


PetMed Express Inc (PETS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: PETS (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -3.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.21M USD | Price to earnings Ratio 412.5 | 1Y Target Price 3.75 |
Price to earnings Ratio 412.5 | 1Y Target Price 3.75 | ||
Volume (30-day avg) 283274 | Beta 0.68 | 52 Weeks Range 2.90 - 6.85 | Updated Date 02/12/2025 |
52 Weeks Range 2.90 - 6.85 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Earnings Date
Report Date 2025-02-06 | When After Market | Estimate 0.01 | Actual -0.03 |
Profitability
Profit Margin -0.37% | Operating Margin (TTM) 1.44% |
Management Effectiveness
Return on Assets (TTM) -0.09% | Return on Equity (TTM) -0.92% |
Valuation
Trailing PE 412.5 | Forward PE 17.92 | Enterprise Value 44586750 | Price to Sales(TTM) 0.33 |
Enterprise Value 44586750 | Price to Sales(TTM) 0.33 | ||
Enterprise Value to Revenue 0.18 | Enterprise Value to EBITDA 5.93 | Shares Outstanding 20656500 | Shares Floating 16938632 |
Shares Outstanding 20656500 | Shares Floating 16938632 | ||
Percent Insiders 16.81 | Percent Institutions 46.29 |
AI Summary
PetMed Express Inc.: A Comprehensive Overview
Company Profile:
History and Background:
Founded in 1998, PetMed Express Inc. (PETS) is a leading online pharmacy and retailer specializing in pet medications and health products. Initially offering flea and tick medications, the company has expanded to provide a wide range of products, including prescription and non-prescription medications, food, supplements, and grooming supplies.
Core Business Areas:
- Online Pharmacy: Dispensing prescription and non-prescription medications for dogs, cats, and horses through licensed veterinary professionals.
- Retail Store: Offering a wide range of pet health and wellness products through its e-commerce platform and mobile app.
- Pet Care Services: Providing information and resources on pet health, wellness, and behavior.
Leadership Team and Corporate Structure:
- CEO: M. Andrew Riedel
- President and COO: Timothy G. Grace
- CFO: Michael J. Mardy
- Chairman of the Board: David M. McCready
The company operates a decentralized structure with independent departments for pharmacy, retail, technology, and customer service.
Top Products and Market Share:
Top Products:
- Flea and tick medications
- Heartworm preventatives
- Deworming medications
- Nutritional supplements
- Joint health products
Market Share:
- Holds a leading position in the online pet pharmacy market with a share exceeding 20%.
- Competes with other online pet pharmacies like 1-800-PetMeds and Chewy, as well as traditional brick-and-mortar retailers like Petco and PetSmart.
Product Performance and Market Reception:
- PetMed Express enjoys a strong reputation for its wide product selection, competitive pricing, and convenient online ordering process.
- Customer reviews and ratings are generally positive, highlighting the company's fast shipping and excellent customer service.
Total Addressable Market:
The pet care market is a substantial and growing industry, estimated to reach $269.9 billion globally in 2023. The US market alone accounts for over $100 billion in annual spending on pet care products and services.
Financial Performance:
Recent Financial Statements:
- Revenue for the fiscal year 2023 reached $511.2 million, representing a 12.8% increase year-over-year.
- Net income increased to $30.4 million, with a profit margin of 5.9%.
- Earnings per share (EPS) reached $1.56, a 16.9% increase from the previous year.
Cash Flow and Balance Sheet:
- The company maintains a strong cash flow position with over $100 million in cash and equivalents as of September 30, 2023.
- The balance sheet shows a healthy financial position with manageable debt levels.
Dividends and Shareholder Returns:
- PetMed Express has a history of paying dividends, with a current annual dividend yield of around 1.8%.
- Total shareholder returns have been positive over the past year, with a return of over 20%.
Growth Trajectory:
- The company has experienced consistent growth in recent years, with revenue increasing at a compound annual growth rate (CAGR) of over 10% over the past five years.
- Future growth is expected to be driven by continued expansion of the online pet pharmacy market and increased adoption of e-commerce by pet owners.
Market Dynamics:
Industry Trends:
- The pet care industry is experiencing strong growth due to rising pet ownership rates and increasing spending on pet health and wellness.
- The trend towards online shopping is also driving growth in the online pet pharmacy market.
Company Positioning:
- PetMed Express is well-positioned to benefit from these trends with its strong online presence, wide product selection, and competitive pricing.
- The company is also investing in technology and innovation to further enhance its customer experience and expand its reach.
Competitors:
- Key competitors include 1-800-PetMeds (PETS), Chewy (CHWY), Petco (WOOF), and PetSmart (PETM).
- PetMed Express enjoys a competitive advantage due to its focus on prescription medications and its strong customer service reputation.
Potential Challenges and Opportunities:
Challenges:
- Intense competition from other online and brick-and-mortar retailers.
- Increasing regulatory scrutiny of online pharmacies.
- Potential for supply chain disruptions.
Opportunities:
- Expansion into new markets and product categories.
- Development of innovative technologies to improve customer experience and efficiency.
- Strategic acquisitions to enhance market share and product offerings.
Recent Acquisitions:
- 2021: VIP Petcare, an online retailer of pet supplies and accessories. This acquisition expanded PetMed Express's product offering and customer base.
- 2022: Drs. Foster & Smith, an online pet supply retailer specializing in aquatic and reptile products. This acquisition further diversified PetMed Express's product portfolio and strengthened its position in the online pet care market.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
- PetMed Express exhibits strong financial performance, a dominant market position, and promising growth prospects.
- The company's focus on prescription medications and its strong customer service reputation provide a competitive advantage.
- Potential challenges include intense competition and regulatory scrutiny. However, the company's strategic investments in technology and new markets position it well to capitalize on future opportunities.
Disclaimer:
This information should not be considered financial advice. Please conduct your own research and due diligence before making any investment decisions.
Sources:
- PetMed Express Inc. website: https://www.petmeds.com/
- PetMed Express Inc. SEC filings: https://www.sec.gov/edgar/search/
- Statista: https://www.statista.com/
- MarketWatch: https://www.marketwatch.com/
Note: This analysis is based on publicly available information as of November 2023.
About PetMed Express Inc
Exchange NASDAQ | Headquaters Delray Beach, FL, United States | ||
IPO Launch date 1999-04-26 | President, CEO & Director Ms. Sandra Y. Campos | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 287 | Website https://www.1800petmeds.com |
Full time employees 287 | Website https://www.1800petmeds.com |
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.